Compare Crocs, Inc. (CROX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Intuitive Surgical, Inc. — how do they compare? Crocs, Inc. trades at $115.16 (market cap $5.60B), while Intuitive Surgical, Inc. trades at $424.55 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 26.2× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Intuitive Surgical, Inc. for 84 Days on average.
| CROX | ISRG | |
|---|---|---|
Market Cap | $5.60B | $146.76B |
Volume | 1,026,773 | 2,529,814 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $592.85 |
52-Week Low | $73.39 | $332.02 |
Typical Hold Time | 96 Days | 84 Days |
Enterprise Value | $7.12B | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $117.64, up 2.12% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but maintains strong fundamentals including a 10.37 P/E ratio and 42.3% ROE. Recent management commentary highlights product innovation and HEYDUDE brand repositioning as growth catalysts. Cash flow trends show consistent operational strength despite recent net income volatility.
The outlook remains cautiously optimistic with analyst consensus targeting $136.78 (16% upside). Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification. The combination of attractive valuation, strong profitability metrics, and positive earnings surprises supports potential long-term appreciation despite near-term technical weakness.
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
